Course: Practical Solutions to Connect the Dots on Bispecific Antibodies for MM Care: A Research-informed Toolkit
CME Credits: 1.00
Released: 2025-08-08
With the inclusion of bispecific antibodies in a rapidly expanding treatment landscape for multiple myeloma (MM), clinicians must become proficient in selecting treatment in the relapsed/refractory setting. Hear from expert clinicians Dr. Ajai Chari and Dr. Hans Lee as they review real-world data from community cancer centers, efficacy and safety data for bispecific antibodies in the relapsed/refractory setting, how to integrate therapy into point-of-care decisions for patients, and monitoring and management protocols for timely detection of adverse events. In addition, a toolkit developed by expert faculty with feedback from practicing clinicians will be available to all participants. The toolkit will guide discussions of aggregate data and collaborative problem-solving on individual and team levels. You can also submit your specific questions to Dr. Chari and Dr. Lee.
View Full Course